- ISIN
- US23725P2092
- CUSIP
- 23725P209
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- IPO Date
- Oct 6, 2014
Highlights
- EPS (TTM)
- $2.13
- PE Ratio
- 3.59
- Total Revenue (TTM)
- $21.19M
- Gross Profit (TTM)
- $11.98M
- EBITDA (TTM)
- -$35.81M
- Year Range
- $5.94 - $17.74
- Target Price
- $16.00
- ROE (TTM)
- 126.98%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
DRIO Performance Chart
DarioHealth Corp. (DRIO) is down 32.8% since the beginning of the year. At $8 per share, DRIO is trading 56.9% below its 52-week high of $18. Investors who bought $1,000 worth of DRIO shares 5 years ago would now be looking at an investment worth $19.
Loading charts...
Returns By Period
DarioHealth Corp. (DRIO) has returned -32.78% so far this year and -42.95% over the past 12 months. Over the last ten years, DRIO has returned -42.62% per year, falling short of the S&P 500 Index benchmark, which averaged 13.66% annually.
DarioHealth Corp.
- 1D
- 0.00%
- 1M
- 2.68%
- YTD
- -32.78%
- 6M
- -35.44%
- 1Y
- -42.95%
- 3Y*
- -54.31%
- 5Y*
- -54.67%
- 10Y*
- -42.62%
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
DRIO Monthly Returns History
Based on dividend-adjusted daily data since Oct 6, 2014, DRIO's average daily return is -0.03%, while the average monthly return is -1.95%.
Historically, 38% of months were positive and 62% were negative. The best month was Jul 2020 with a return of +95.3%, while the worst month was Oct 2023 at -61.0%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 6 months.
On a daily basis, DRIO closed higher 44% of trading days. The best single day was Jan 7, 2025 with a return of +79.6%, while the worst single day was Mar 4, 2016 at -42.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -11.95% | 19.46% | -33.00% | -10.91% | 8.47% | -1.29% | -32.78% | ||||||
| 2025 | -21.13% | 12.24% | -12.03% | 16.81% | 0.00% | -6.31% | -14.48% | -17.02% | 82.44% | -19.37% | -14.65% | -4.69% | -27.62% |
| 2024 | 9.88% | 7.41% | -24.63% | -7.19% | 0.70% | -16.78% | -9.24% | -25.00% | 38.27% | -14.28% | -17.82% | -0.37% | -54.30% |
| 2023 | 29.44% | -16.97% | -10.43% | -18.20% | 15.73% | 2.82% | -6.98% | -16.09% | 4.79% | -60.98% | -5.47% | 42.15% | -59.81% |
| 2022 | -32.38% | -16.76% | -20.00% | -15.07% | 34.07% | -7.67% | -0.49% | -21.93% | -2.94% | -4.32% | 11.96% | -13.71% | -67.00% |
| 2021 | 51.57% | 22.81% | -27.59% | 12.56% | -24.95% | 31.28% | -30.52% | -9.10% | 1.19% | 19.78% | -4.40% | -17.02% | -9.24% |
Benchmark Metrics
DarioHealth Corp. has an annualized alpha of -16.00%, beta of 0.84, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since October 07, 2014.
- This stock participated in 181.16% of S&P 500 Index downside but only -51.00% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -16.00%
- Beta
- 0.84
- R²
- 0.02
- Upside Capture
- -51.00%
- Downside Capture
- 181.16%
Return for Risk
Risk / Return Rank
DRIO ranks 23 for risk / return — below 23% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for DarioHealth Corp. (DRIO) and compare them to S&P 500 Index.
| DRIO | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.66 | ||
| Sortino ratioReturn per unit of downside risk | -3.17 | ||
| Omega ratioGain probability vs. loss probability | 0.99 | 1.41 | -0.42 |
| Calmar ratioReturn relative to maximum drawdown | -0.68 | 2.93 | -3.61 |
| Martin ratioReturn relative to average drawdown | -1.17 | 13.52 | -14.69 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the DarioHealth Corp.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the DarioHealth Corp. was 99.86%, occurring on Sep 18, 2025. The portfolio has not yet recovered.
The current DarioHealth Corp. drawdown is 99.83%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 bear market2025 | -99.86%Sep 2025 | 10y 11mo | — | 11y 8moOct 2014 - now |
Drawdown Indicators
| DRIO | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.86% | -56.78% | -43.08% |
Max Drawdown (1Y)Largest decline over 1 year | -63.29% | -9.10% | -54.19% |
Max Drawdown (3Y)Largest decline over 3 years | -92.88% | -18.90% | -73.98% |
Max Drawdown (5Y)Largest decline over 5 years | -98.63% | -25.43% | -73.20% |
Max Drawdown (10Y)Largest decline over 10 years | -99.72% | -33.92% | -65.80% |
Current DrawdownCurrent decline from peak | -99.83% | -0.74% | -99.09% |
Average DrawdownAverage peak-to-trough decline | -86.13% | -10.72% | -75.41% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 36.77% | 1.97% | +34.80% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of DarioHealth Corp. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how DarioHealth Corp. is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for DRIO, comparing it with other companies in the Diagnostics & Research industry. Currently, DRIO has a P/E ratio of 3.6. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for DRIO relative to other companies in the Diagnostics & Research industry. Currently, DRIO has a P/S ratio of 13.4. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with DRIO
Add DarioHealth Corp. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with DRIO